Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (1y) (2011 - 2025)
Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 143.40% |
| 10 | Madrigal Pharmaceuticals | 16.20 Bn | 15.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -117.85% |
| Sep 30, 2025 | 249.18% |
| Dec 31, 2024 | 41.12% |
| Sep 30, 2024 | -243.95% |
| Jun 30, 2024 | 89.86% |
| Mar 31, 2024 | 920.00% |
| Dec 31, 2023 | 3,472.41% |
| Sep 30, 2023 | 927.27% |
| Jun 30, 2023 | -33.01% |
| Mar 31, 2023 | -32.69% |
| Dec 31, 2022 | -74.34% |
| Sep 30, 2022 | -34.00% |
| Jun 30, 2022 | 5,050.00% |
| Mar 31, 2022 | 18.18% |
| Dec 31, 2021 | 1,030.00% |
| Sep 30, 2021 | 1,566.67% |
| Jun 30, 2021 | -71.43% |
| Mar 31, 2021 | -85.99% |
| Dec 31, 2020 | -98.84% |
| Sep 30, 2020 | 250.00% |